The study aims to understand how to best provide a medicine called Cabotegravir (CAB) for preventing HIV. HIV is a virus that affects the immune system. Cabotegravir is a *pre-exposure prophylaxis (PrEP)*, which means it helps prevent getting HIV before being exposed to it. The study has two groups: Patient Study Participants (PSPs) are the people receiving the CAB medicine, and Staff Study Participants (SSPs) are the staff helping to give the medicine.
To join the study, participants must be at least 18 years old, HIV-negative, and have never had CAB before. They should be identified as female at birth or as a transgender female and identify as African American/Black. Those who are HIV-positive or involved in similar studies cannot join.
- Study Length: The duration and number of visits are not specified, but participants will be involved as long as required to evaluate the medicine's delivery.
- Compensation: Details about compensation for participation are not provided.
- Risks: Participants might face risks associated with taking CAB or being part of a clinical study.
How understandable was the trial content above?
Hard to understand
Easy to understand